论文部分内容阅读
目的:检测胃癌肝转移患者治疗前后的血浆可溶性血管内皮细胞生长因子(VEGF)水平,并探讨其临床意义。方法:采用定量酶联免疫吸附试验双抗体夹心法检测43例胃癌肝转移患者治疗前后和20例浅表性胃炎患者(对照组)的血浆可溶性VEGF水平。结果:胃癌肝转移患者血浆可溶性VEGF水平显著高于对照组。经治疗后病情好转的胃癌肝转移患者[疗效评价为完全缓解(CR)或部分缓解(PR)],其血浆可溶性VEGF水平较治疗前明显下降,两者之间的差异有统计学意义(P<0.05)。治疗后病情进展的胃癌肝转移患者[疗效评价为疾病进展(PD)],其血浆可溶性VEGF水平较治疗前明显升高,两者之间的差异有统计学意义(P<0.05)。在经治疗后病情稳定的胃癌肝转移患者[疗效评价为疾病稳定(SD)],其血浆可溶性VEGF水平与治疗前的差异无统计学意义。结论:用ELISA方法检测血浆可溶性VEGF浓度对于评价胃癌肝转移的治疗疗效有一定的参考价值。
Objective: To detect the level of plasma soluble vascular endothelial growth factor (VEGF) in patients with liver metastasis of gastric cancer before and after treatment, and to explore its clinical significance. Methods: The levels of plasma soluble VEGF in 43 patients with hepatic metastasis of gastric cancer and 20 patients with superficial gastritis (control group) were measured by quantitative enzyme-linked immunosorbent assay (ELISA) double antibody sandwich method. Results: The plasma level of soluble VEGF in patients with liver metastasis of gastric cancer was significantly higher than that of the control group. After treatment, patients with metastatic gastric cancer with liver metastases [efficacy evaluation was complete remission (CR) or partial remission (PR)], the plasma soluble VEGF level was significantly lower than before treatment, the difference between the two was statistically significant (P <0.05). After treatment, the progression of gastric cancer patients with liver metastasis [evaluation of the disease progression (PD)], the plasma soluble VEGF levels were significantly higher than before treatment, the difference between the two was statistically significant (P <0.05). After treatment, stable gastric cancer patients with liver metastases [evaluation of the disease as stable disease (SD)], the plasma level of soluble VEGF and no significant difference between before treatment. Conclusion: The ELISA method for the determination of plasma soluble VEGF levels for the evaluation of the efficacy of treatment of gastric cancer liver metastasis of a certain reference value.